Agenus (NASDAQ:AGEN) reported its financial results for the fourth quarter and full year ended December 31, 2025, marking a transition from a purely clinical-stage company to one generating initial pre-commercial revenue.
The Lexington, Massachusetts-based immunotherapy leader recognized $4.2 million in revenue for the year from regulatory-authorized early access programs for its botensilimab (BOT) and balstilimab (BAL) combination.
This program, which targets tumors traditionally resistant to standard checkpoint inhibitors, has now expanded into more than 30 countries following over 200 physician inquiries.
A key operational highlight was the launch of the BATTMAN Phase 3 registrational trial.
This global study is evaluating BOT+BAL in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a population with significant unmet medical need.
Clinical data previously presented by the company demonstrated a 42% two-year overall survival rate in this group—nearly triple the survival rates historically associated with standard-of-care therapies.
On the financial front, Agenus reported fourth-quarter 2025 operating income of $14.4 million, aided by a significant strategic collaboration with Zydus Lifesciences.
The partnership, which closed in January 2026, provided an initial $91 million in upfront capital and a $20 million contingent payment triggered in March 2026.
This infusion of capital, along with dedicated U.S. biologics manufacturing capacity secured through the deal, is designed to support the "commercial readiness" phase of the BOT+BAL program.
For the full year 2025, total revenue—including non-cash royalty revenue and early access sales—reached $110 million, compared to $80 million in 2024.
While the company reported a full-year operating loss of $20.2 million, management emphasized that the improved balance sheet and expanding early access footprint in France (which now includes ovarian cancer and sarcoma) provide a stable foundation for the upcoming year.
Agenus is now preparing for formal regulatory submissions in the United States and Europe as it continues to build the real-world evidence required for full market authorization.